Remote Ischemic Conditioning Combined With Endovascular Stenting for Symptomatic Intracranial Atherosclerotic Stenosis
Launched by TIANJIN HUANHU HOSPITAL · Dec 15, 2022
Trial Information
Current as of January 14, 2025
Not yet recruiting
Keywords
ClinConnect Summary
Intracranial atherosclerotic stenosis (ICAS) is one of the leading causes of ischemic stroke, and its incidence varies widely among different ethnic groups. ICAS may represent approximately 10% of ischemic stroke in Caucasians and even be responsible for up to 50% in Chinese population. Recurrent stroke risks are as high as 23% 1 year after transient ischemic stroke (TIA) or stroke in patients with a stenosis of 70% or more. The Chinese IntraCranial AtheroSclerosis (CICAS) study indicated the prevalence of ICAS was 46.6%; Patients with ICAS had more severe stroke at admission and stayed lon...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patient admitted from Jan. 1st 2023 to Jan. 1st 2025;
- • 2. Age ≥ 18;
- • 3. Intracranial atherosclerosis stenosis measured as ≥70% by digital subtraction angiography or by other noninvasive methods, such as transcranial doppler, computed tomography angiography, or magnetic resonance angiography;
- • 4. A history of stroke/transient ischemic attack attributed to ICAS;
- • 5. Verbal and written informed consent is provided at the time of admission by patients or their legally authorized representatives.
- Exclusion Criteria:
- • 1. Stenosis of other causes;
- • 2. Prior ipsilateral stroke with residual deficits;
- • 3. Uncontrolled hypertension (defined as systolic blood pressure ≥200 mm Hg despite medications at enrollment);
- • 4. Peripheral vascular disease (especially subclavian arterial and upper limb artery stenosis or occlusion).
Trial Officials
Ming Wei, PhD
Principal Investigator
Tianjin Huanhu Hospital
About Tianjin Huanhu Hospital
Tianjin Huanhu Hospital is a leading medical institution in Tianjin, China, dedicated to providing high-quality healthcare services and advancing medical research. As a clinical trial sponsor, the hospital is committed to fostering innovation in medical treatments and therapies through rigorous scientific investigation. With a multidisciplinary team of experienced healthcare professionals and researchers, Tianjin Huanhu Hospital adheres to the highest ethical standards and regulatory guidelines to ensure patient safety and data integrity. The hospital’s state-of-the-art facilities and collaborative approach facilitate the successful execution of clinical trials, contributing to the global advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tianjin, Tianjin, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials